Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimagrumab in Overweight/Obese T2D
NCT03005288Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2017
- Primary completion
- Mar 2019
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of bimagrumab in type 2 diabetes mellitus (T2DM), obesity, sponsored by Novartis. Started Feb 2017; status: completed.
02
Drugs
bimagrumab
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT03005288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03005288.